The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ACST | +0.32% | N/A | N/A | -99% |
| S&P | +19.61% | +98.99% | +14.75% | +446% |
Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland and Pierre Lemieux on February 1, 2002 and is headquartered in Laval, Canada.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | 0.0% |
| Gross Profit | -$0.00M | -100.0% |
| Market Cap | $41.07M | 0.0% |
| Market Cap / Employee | $10.27M | 0.0% |
| Employees | 4 | 0.0% |
| Net Income | -$3.36M | -28.5% |
| EBITDA | -$3.09M | 37.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $20.01M | 3.2% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.00M | 0.0% |
| Short Term Debt | $0.00M | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -14.78% | 1.3% |
| Return On Invested Capital | -28.33% | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$1.80M | 49.9% |
| Operating Free Cash Flow | -$1.80M | 49.9% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change | |
|---|---|---|---|---|---|
| Price to Book | 0.68 | 0.44 | 0.61 | - | |
| Price to Tangible Book Value | 5.52 | 8.05 | 2.35 | - | |
| Enterprise Value to EBITDA | -4.01 | -8.64 | -2.87 | -8.84 | 250.76% |
| Return on Equity | -18.9% | -22.9% | -14.9% | -16.8% | -9.57% |
| Total Debt | $0.00M | $0.00M | $0.00M | $0.00M | - |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
